Citations

Showing 10 of 108104 citations.

Advances in Recapitulating Alzheimer’s Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models
Hasan, Md Fayad , Trushina, Eugenia , Trushina, Eugenia

Mayo Clinic

Brain Sciences | April 26, 2022 | Volume: 12 | Issue: 5 | Pages: 552

10.3390/brainsci12050552 | PMID 35624938 Get It

Alzheimer’s disease (AD) is an incurable neurodegenerative disorder and the leading cause of death among older individuals. Available treatment strategies only temporarily mitigate symptoms without modifying disease progression. Recent studies revealed the multifaceted neurobiology of AD and shifted the target of drug development. Established animal models of AD are mostly tailored to yield a subset of disease phenotypes, which do not recapitulate the complexity of sporadic late-onset AD, the most common form of the disease. The use of human induced pluripotent stem cells (HiPSCs) offers unique opportunities to fill these gaps. Emerging technology allows the development of disease models that recapitulate a brain-like microenvironment using patient-derived cells. These models retain the individual’s unraveled genetic background, yielding clinically relevant disease phenotypes and enabling cost-effective, high-throughput studies for drug discovery. Here, we review the development of various HiPSC-based models to study AD mechanisms and their application in drug discovery.
MaxSpliZer: a Tool to Predict Effects of Splice Variants Based on the Maximum Entropy Model
Saadatagah, Seyedmohammad , Shahnazar, Reza , Alhalabi, Lubna, Miller, Alexandra A. , Hamed, Marwan , Kullo, Iftikhar, Sherafati, Alborz

Mayo Clinic

No container title available | April 26, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165095761.17308137/v2 Get It

The Clinical Genome Resource Consortium (ClinGen) recommends MaxEntScan (MES) model to predict effects of LDLR splice variants. We developed “MaxSpliZer”, a software tool to automate implementation of MES and validated it using ClinVar and UK-Biobank (UKBB) data. We tested concordance of MaxSpliZer predictions with ClinVar classifications of pathogenicity of variants in LDLR and FBN1 with potential effect on splicing. We also annotated LDLR splice variants in 200,618 UKBB participants, categorizing them using MaxSpliZer as deleterious (n=90) and non-deleterious (n=7,404). Low-density lipoprotein cholesterol (LDL-C) levels were compared in these two groups after adjustment for lipid lowering medication use. MaxSpliZer prediction was concordant with the ClinVar classification in 96% of LDLR variants and 98% of FBN1 variants. In the UKBB, splice variants predicted as deleterious by MaxSpliZer had higher LDL-C than non-deleterious splice variants (158.7±47.4 vs. 146.0±34.8mg/dL, p-value = 0.014). Compared to manual curation time of 12±7 min per variant, MaxSpliZer took 0.52±0.11 min for single entries and 1.5 s per variant for biobank-scale data. MaxSpliZer, a software tool that implements MES based on the ClinGen guideline, can accurately classify splice variants in a rapid automated fashion.
Estimating the US pericarditis prevalence using national health encounter surveillance databases
LeWinter, Martin M. , Magestro, Matthew, DerSarkissian, Maral , Duh, Mei Sheng , Chang, Rose, Kponee-Shovein, Kalé , Muthukumar, Aruna , Hu, Xingdi, Lim-Watson, Michelle , Luis, Sushil Allen , Muthukumar, Aruna , Klein, Allan L.

Mayo Clinic

Current Medical Research and Opinion | April 26, 2022 | Volume: 38 | Issue: 8 | Pages: 1385-1389

10.1080/03007995.2022.2070381 | PMID 35470753 Get It

Incremental Prognosis by Left Atrial Functional Assessment: The Left Atrial Coupling Index in Patients With Floppy Mitral Valves
Essayagh, Benjamin , Benfari, Giovanni, Antoine, Clémence, Maalouf, Joseph, Pislaru, Sorin, Thapa, Prabin, Michelena, Héctor I. , Enriquez‐Sarano, Maurice , Benfari, Giovanni , Michelena, Hector I , Enriquez-Sarano, Maurice , Benfari, Giovanni , Essayagh, Benjamin , Antoine, Clémence, Maalouf, Joseph, Pislaru, Sorin, Thapa, Prabin

Mayo Clinic

Journal of the American Heart Association | April 26, 2022 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/jaha.121.024814 | PMID 35470696 Get It

Background Emerging data suggest important prognostic value to left atrial (LA) characteristics, but the independent impact of LA function on outcome remains unsubstantiated. Thus, we aimed to define the incremental prognostic value of LA coupling index (LACI), coupling volumetric and mechanical LA characteristics and calculated as the ratio of left atrial volume index to tissue Doppler imaging a′, in a large cohort of patients with isolated floppy mitral valve. Methods and Results All consecutive 4792 patients (61±16 years, 48% women) with isolated floppy mitral valve in sinus rhythm diagnosed at Mayo Clinic from 2003 to 2011, comprehensively characterized and with prospectively measured left atrial volume index and tissue Doppler imaging a′ in routine practice, were enrolled, and their long‐term survival analyzed. Overall, LACI was 5.8±3.7 and was <5 in 2422 versus ≥5 in 2370 patients. LACI was independently higher with older age, more mitral regurgitation (no 3.8±2.3, mild 5.1±3.0, moderate 6.5±3.8, and severe 7.8±4.3), and with diastolic (higher E/e′) and systolic (higher end‐systolic dimension) left ventricular dysfunction (all P ≤0.0001). At diagnosis, higher LACI was associated with more severe presentation (more dyspnea, more severe functional tricuspid regurgitation, and elevated pulmonary artery pressure, all P ≤0.0001) independently of age, sex, comorbidity index, ventricular function, and mitral regurgitation severity. During 7.0±3.0 years follow‐up, 1146 patients underwent mitral valve surgery (94% repair, 6% replacement), and 880 died, 780 under medical management. In spline curve analysis, LACI ≥5 was identified as the threshold for excess mortality, with much reduced 10‐year survival under medical management (60±2% versus 85±1% for LACI <5, P <0.0001), even after comprehensive adjustment (adjusted hazard ratio, 1.30 [95% CI, 1.10–1.53] for LACI ≥5; P =0.002). Association of LACI ≥5 with higher mortality persisted, stratifying by mitral regurgitation severity of LA enlargement grade (all P <0.001) and after propensity‐score matching ( P =0.02). Multiple statistical methods confirmed the significant incremental predictive power of LACI over left atrial volume index (all P <0.0001). Conclusions LA functional assessment by LACI in routine practice is achievable in a large number of patients with floppy mitral valve using conventional Doppler echocardiographic measurements. Higher LACI is associated with worse clinical presentation, but irrespective of baseline characteristics, LACI is strongly, independently, and incrementally determinant of outcome, demonstrating the crucial importance of LA functional response to mitral valve disease.
Impact of obesity on the molecular response to a single bout of exercise in a preliminary human cohort
Vanderboom, Patrick M. , Zhang, Xiaoyan , Hart, Corey R., Gries, Kevin J. , Heppelmann, Carrie J. , Liu, Yuanhang , Dasari, Surendra , Vanderboom, Patrick, Lanza, Ian R , Kunz, Hawley , Lanza, Ian R.

Mayo Clinic

Obesity | April 26, 2022 | Volume: 30 | Issue: 5 | Pages: 1091-1104

10.1002/oby.23419 | PMID 35470975 Get It

AbstractObjectiveThe health benefits of exercise are well documented, but several exercise‐response parameters are attenuated in individuals with obesity. The goal of this pilot study was to identify molecular mechanisms that may influence exercise response with obesity.MethodsA multi‐omics comparison of the transcriptome, proteome, and phosphoproteome in muscle from a preliminary cohort of lean individuals (n = 4) and individuals with obesity (n = 4) was performed, before and after a single bout of 30 minutes of unilateral cycling at 70% maximal oxygen uptake (VO2 peak). Mass spectrometry and RNA sequencing were used to interrogate the proteome, phosphoproteome, and transcriptome from muscle biopsy tissue.ResultsThe main findings are that individuals with obesity exhibited transcriptional and proteomic signatures consistent with reduced mitochondrial function, protein synthesis, and glycogen synthesis. Furthermore, individuals with obesity demonstrated markedly different transcriptional, proteomic, and phosphoproteomic responses to exercise, particularly biosynthetic pathways of glycogen synthesis and protein synthesis. Casein kinase II subunit alpha and glycogen synthase kinase‐3β signaling was identified as exercise‐response pathways that were notably altered by obesity.ConclusionsOpportunities to enhance exercise responsiveness by targeting specific molecular pathways that are disrupted in skeletal muscle from individuals with obesity await a better understanding of the precise molecular mechanisms that may limit exercise‐response pathways in obesity.
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
He, Zhijian , Deva, Sanjeev , Hung, Tak, Clarke, Katriona, Chao, Tsu‐Yi , Dai, Ming‐Shen , Yeh, Hsien‐Tang , Kramer, Douglas, Kwan, Rudolf, Cutler, David L. , Zhi, Jay, Jackson, Christopher , Segelov, Eva , Wee, Wen , Chan, Wing‐Kai

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | April 26, 2022 | Volume: 11 | Issue: 7 | Pages: 867-879

10.1002/psp4.12799 | PMID 35470967 Get It

AbstractOraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous paclitaxel. Here we describe the population pharmacokinetics (popPK) analyses for oral paclitaxel in patients with advanced/metastatic solid tumors to characterize pharmacokinetic (PK) profiles and quantify sources of PK variability. The best fit popPK model for oral paclitaxel, based on data from seven clinical studies (197 patients with advanced/metastatic solid tumors), involves a linear two‐compartment structural model containing first‐order absorption with a short lag time and first‐order elimination as well as a log additive error. In this popPK model, lower population estimates of central volume for Asian patients versus Caucasian patients did not translate into clinical meaningful differences in oral paclitaxel exposure. Age, sex, body weight or surface area, mild hepatic impairment, and mild to moderate renal impairment had no clinically meaningful effects on the systemic exposure of oral paclitaxel. Simulations were performed on clinical therapeutic dose (oral paclitaxel 205 mg/m2 once daily ×3 days per week) to predict exposure of oral paclitaxel and to support treatment benefits observed in a pivotal phase III trial.
Utilization of cardiac imaging in sarcoidosis
Bois, John P. , Elwazir, Mohamed Y. , Chareonthaitawee, Panithaya

Mayo Clinic

Expert Review of Cardiovascular Therapy | April 26, 2022 | Volume: 20 | Issue: 4 | Pages: 253-266

10.1080/14779072.2022.2069560 | PMID 35469519 Get It

A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse
Greenberg, Benjamin , Bowen, James D. , Caggiano, Anthony O. , Warrington, Arthur E. , Zhao, Ping , Greenberg, Benjamin M , Álvarez, Enrique , Rodriguez, Moses , Eisen, Andrew

Mayo Clinic

Multiple Sclerosis Journal - Experimental, Translational and Clinical | April 26, 2022 | Volume: 8 | Issue: 2 | Pages: No page available

10.1177/20552173221091475 | PMID 35496758 Get It

Background Recombinant human immunoglobulin M22 (rHIgM22) has promoted remyelination in animal models and was well tolerated in people with clinically stable multiple sclerosis. Objective Safety/tolerability of a single rHIgM22 dose was investigated following an acute relapse and to determine whether this enhanced CNS/CSF concentrations. Methods Adults (N = 27) with acute relapse were assigned to rHIgM22 (0.5 or 2.0 mg/kg) or placebo. Study included screening/steroid administration periods and 10 study visits over 6 months. rHIgM22 CSF concentrations were assessed on days 2 and 29. Pharmacokinetic and safety samples were taken for up to 60 days. Assessments included adverse events and other clinical measures. Brain magnetic resonance imaging was performed with/without gadolinium. Results rHIgM22 CSF levels were consistent with dose-dependent concentration on both days 2 and 29. Infusion was generally well tolerated during an acute relapse. Immunogenicity was mild. Most adverse events did not appear to be dose dependent, were mild/moderate, and were events often associated with multiple sclerosis. Conclusion Although limited by high variability and small sample size, the data suggest enhanced CNS uptake associated with a drop in CSF levels. This study demonstrated safety of an antibody directed to myelin and oligodendrocytes in the course of active demyelinating disease. Further research into rHIgM22 is warranted. ClinicalTrials.gov: NCT02398461 https://clinicaltrials.gov/ct2/show/NCT02398461
143 User Characteristics of Unique Men's Health Website
Alom, Mulham , Collins, S, Nelson, K. , Carlson, Stephanie K., Tentis, E, Ziegelmann, M., Trost, L, Köhler, Tobias , Nelson, K, Helo, Sevann , Trost, L

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S74-S75

10.1016/j.jsxm.2022.01.407 Get It

ABSTRACT Introduction Covid-19 has helped drive all forms of medicine away from traditional brick and mortar medical interactions. Given the availability of online services to obtain treatments for ED, we developed a website to facilitate patient education, triage and men's health appointment scheduling. Objective We sought to assess characteristics of men who utilized a novel website to treat their ED. Methods We report on 50 patients who ultimately booked and attended appointments (video or in person) for erectile dysfunction. Patients found our website through our institution's main informational ED pages or through youtube links from our men's health video playlist library. Patients create an institutional account and are then asked a series of MD created questions designed to streamline patient triage and complete the majority of chart documentation ahead of the appointment. Patients are then sent videos relevant to their condition and future appointment options. Results 2300 users investigated the ED portion of the website with 1.8% of patients ultimately following through with an appointment. 13% of patients who explored the ED portion of the site created a user account that allows a questionnaire to be taken. 90% of men who began the ED questionnaire completed with a mean time of 11 minutes. 52% of men offered an appointment based on their responses completed the patient scheduling form. 71% of traffic was on mobile devices with 29% on desktop/tablet. Site use by time of day is shown in figure 1. Mean age of patients was 53. 92% of patients had ED that occurred &gt; 6 months. Mean SHIM score was 8.2 (IQR 4-12). 80% of participants had both desire and opportunity for sexual activity, 20% did not meet both criteria and thus SHIM scores were less valid for these men. Of the users 28% had never tried pde5s, 32% had partial success with pde5s, 24% could not tolerate or afford pde5s and 42% had unsatisfactory results with pde5s. PDE5 naïve patients were seen by an internal medicine MD specializing in men's health, 10 were seen by surgeons as they requested IPPs and the rest were seen by a combination of men's health APPS and urology attendings for second line treatments and penile doppler. Interestingly, 66% of men were interested in undergoing penile doppler to better understand the etiology of their ED. Hypertension (40%) and diabetes (22%) were the most common medical comorbidities. 36% of the cohort had a strong family history of cardiac disease. Conclusions Men with ED can be effectively triaged through a website application. Most men with pde5 refractory ED wish to pursue penile doppler. The majority of patients seen had watched educational video material ahead of time, facilitating a more sophisticated and streamlined patient interaction. Disclosure No
119 Current Practices in High and Low Volume Centers Regarding Corporotomy Localization During Penoscrotal Inflatable Penile Implant Surgery
Barnard, J, Renterghem, K. Van, Jacobs, B, Yafi, FA, Barnard, J, Barnard, J, Osmonov, Daniar , Ralph, David , Ziegelmann, Matthew , Wang, R, Kannady, Chris, Lentz, A, García, E. Lutz, Adrianne, R, Bettochi, Carlo, Hatzichristodoulou, G, Gross, Madeleine, Faix, A. , Otero, JR, Barnard, John Taylor , Barnard, J, Barnard, J, Barnard, J, Venturino, Luca , WANG, RY, Lentz, A, Adrianne, R., Hatzichristodoulou, Georgios , Martínez‐Salamanca, Juan Ignacio

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S60-S62

10.1016/j.jsxm.2022.01.383 Get It

ABSTRACT Introduction Literature concerning corporotomy location in multi-component inflatable penile prosthetic surgery via a penoscrotal approach is scarce if not non-existent. However, corporotomy location represents an important issue that may influence immediate and long-term outcomes regarding patient and partner satisfaction as well as device durability. Objective To report practices in low- and high-volume penile implant centers regarding corporotomy location. Methods Data from 18 (13 European and 5 American) implant centers were collected retrospectively between September 1st, 2018 and August 31st, 2019. Variables included: intraoperative proximal and distal corpus cavernosum length measurement, total corporal length measurement, total penile implant cylinder length, and length of rear tip extenders. Additionally, patient characteristics, indication for penile implant, operative time, type of implant utilized, reservoir characteristics and short term complications were reported. Results 809 virgin penile implant cases were included in the analysis. Mean age of participants was 61.5 +/- 9.6 years old. In total, 299 AMS 700TM (Boston Scientific) and 510 Coloplast Titan® devices were implanted. The mean proximal/distal corporal measurement ratio during corporotomy was 0.93 +/- 0.29. A statistically significant correlation between lower proximal /distal measurement ratio and higher age (p=0.0013), lower BMI (p&lt;0.0001), use of rear tip extenders (RTE) (p=0.04), lower RTE length (p&lt;0.0001) and absence of diabetes (p=0.0004) was reported. In a 3-month follow up period 49 complications and 37 revision procedures were reported. Conclusions This is the first study reporting and evaluating the current practices regarding corporotomy location during IPP placement in a multicenter cohort, particularly when including such a high number of patients. Nevertheless, the retrospective design limits the study outcomes. Even in experienced hands proximal length measurement in relation to distal length measurement in penoscrotal IPP surgery is in many cases sub-optimal, particularly when the tubing-cylinder connection of each device is taken into account. Disclosure No